AbCellera Biologics Inc. Q3 2026 Earnings Recap

AbCellera reported Q3 results centered on positive Phase 2 data for ABCL635, with a 4-week placebo-adjusted reduction of 5.3 moderate-to-severe hot flashes per day. The stock was roughly flat after earnings, down 0.3%, indicating a neutral market reaction.

Key Takeaways

• ABCL635 reduced daily moderate-to-severe hot flashes by 8.8 from baseline at week 4, versus 3.5 for placebo; the placebo-adjusted reduction was 5.3 events, or 50% of baseline.
• Hot-flash severity fell by 1.4 points with ABCL635 and 0.3 points with placebo, a 1.1-point placebo-adjusted difference.
• At week 4, 37% of ABCL635 participants had complete resolution of moderate-to-severe events, versus 2.2% on placebo; 78% had a reduction of more than 75%.
• Management said the study showed no clear gastrointestinal or liver toxicity signal. Adverse events were numerically more frequent with ABCL635, including headache and fatigue; reported fatigue events were mild.
• The company said it is committed to advancing ABCL635 into late-stage development next year.